New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes

By Dennis Thompson HealthDay ReporterTHURSDAY, April 16, 2026 (HealthDay News) — New anti-amyloid drugs approved to treat ...
PhillyVoice

Alzheimer's drugs have no meaningful effect, new analysis says. But other researchers are criticizing the study

Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.
The BMJ

Alzheimer’s drugs targeting amyloid do not produce clinically meaningful effects, concludes Cochrane review

Alzheimer’s drugs targeting amyloid β proteins “do not produce clinically meaningful positive effects” and slightly increase ...
Science Media Centre

expert reaction to Cochrane review of anti-amyloid monoclonal antibodies for Alzheimer’s Disease

‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ was published in the Cochrane Database of Systematic Reviews at ...

Do Alzheimer’s Drugs Work? New Analysis Raises Doubts

A new medical review finds "trivial" benefits for amyloid drugs. See why U.S. experts say these findings may not tell the ...
Scientific American

Effect of antiamyloid Alzheimer’s drugs ‘absent or trivial,’ Cochrane review finds

These drugs were hailed by proponents as breakthroughs in the fight to treat Alzheimer’s disease, but a new independent ...